NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Closed System Drug Transfer Devices to 2026

出版商 Greystone Research Associates 商品編碼 985625
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
封閉式藥物傳輸系統(CSTD):∼2026年 Closed System Drug Transfer Devices to 2026
出版日期: 2021年02月02日內容資訊: 英文




  • 封閉藥物轉移系統(CSTD)的預測
  • 執行摘要
  • 癌症治療趨勢
  • 癌症治療的演變
  • 化學療法
  • 免疫療法
  • 細胞毒性藥物的作用演變
  • 重組藥物生態系統
  • CSTD市場動態
  • 藥房
  • POC(護理點)
  • 技術因素
  • CSDT競爭情況
  • 風險與機遇
  • 細胞毒性藥物市場
  • 不斷變化的處方因素
  • 封閉式藥物轉移的設計因素
  • 癌症藥物的安全性
  • 材料選擇問題
  • 毒品重建
  • 癌症治療的用途和數量
  • 藥物特異性劑量變化和個體劑量
  • CSDT設備性能因素
  • 圍攻
  • 測試協議
  • CSDT設備:主要市場領域
  • 教學醫院
  • 社區/社區醫院
  • 癌症中心/診所
  • 封閉式藥物轉移:設備評估
  • 市場評估和預測
  • 區域數據
  • 公司簡介
Product Code: CST929F

Technology-driven Patient & Caregiver Safety

The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that - in spite of promising new drugs based on therapeutic antibodies - continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues.

What You Will Learn:

  • What are the key segments and addressable markets that comprise the market for cytotoxic drug delivery?
  • What are the major therapeutic demand drivers for cytotoxic drug therapeutics?
  • What are the design factors and technologies that are being used in commercial and development-stage closed drug transfer systems?
  • What is the market share and product position in the market and what will it look like in 2026?
  • Who are the companies behind the current generation of cytotoxic transfer devices and what are their business models?
  • What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging closed system drug transfer devices?
  • What is the impact of economic, technology, and regulatory factors on CSDT device demand?

Table of Contents

  • Closed System Drug Transfer Devices to 2026
  • Executive Summary
  • Oncology Drug Trends
  • The Evolution in Oncology Therapeutics
  • Chemotherapy
  • Immunotherapy
  • The Evolving Role of Cytotoxic Drugs
  • The Recombinant Drug Ecosystem
  • CSTD Market Dynamics
  • Pharmacy
  • Point-of-Care
  • Technology Factors
  • CSDT Competitive Landscape
  • Risks and Opportunities
  • The Market for Cytotoxic Drugs
  • Evolving Prescribing Factors
  • Closed System Drug Transfer Design Factors
  • Oncology Therapeutics Medication Safety
  • Material Selection Issues
  • Drug Reconstitution
  • Oncology Drug Administration and Dosing
  • Drug-Specific Dosing Modification and Individualized Dosing
  • CSDT Device Performance Factors
  • Vapor Containment
  • Testing Protocols
  • CSDT Devices - Key Market Segments
  • Teaching Hospitals
  • Regional/Community Hospitals
  • Oncology Centers/Clinics
  • Closed Drug Transfer - Device Assessments
  • Market Assessments and Forecasts
  • Geographic Data
  • Company Profiles